These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8807890)

  • 1. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
    Mello JA; Acharya S; Fishel R; Essigmann JM
    Chem Biol; 1996 Jul; 3(7):579-89. PubMed ID: 8807890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of DNA mismatch repair in platinum drug resistance.
    Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
    Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin.
    Trimmer EE; Essigmann JM
    Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
    Zhu G; Myint M; Ang WH; Song L; Lippard SJ
    Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of the Escherichia coli UvrAB proteins to the DNA mono- and diadducts of cis-[N-2-amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II ) and cisplatin. Analysis of the factors controlling recognition and proof of monoadduct-mediated UvrB-DNA cross-linking.
    Lambert B; Jestin JL; Bréhin P; Oleykowski C; Yeung AT; Mailliet P; Prétot C; Le Pecq JB; Jacquemin-Sablon A; Chottard JC
    J Biol Chem; 1995 Sep; 270(36):21251-7. PubMed ID: 7673159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
    Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
    Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition and repair of DNA-cisplatin adducts.
    Woźniak K; Błasiak J
    Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J; Novakova O; Farrell N; Brabec V
    Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
    Zdraveski ZZ; Mello JA; Farinelli CK; Essigmann JM; Marinus MG
    J Biol Chem; 2002 Jan; 277(2):1255-60. PubMed ID: 11705991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human MutSalpha specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts.
    Li GM; Wang H; Romano LJ
    J Biol Chem; 1996 Sep; 271(39):24084-8. PubMed ID: 8798646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MutS inhibits RecA-mediated strand exchange with platinated DNA substrates.
    Calmann MA; Marinus MG
    Proc Natl Acad Sci U S A; 2004 Sep; 101(39):14174-9. PubMed ID: 15375217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
    Kaspárková J; Brabec V
    Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
    Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
    Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA.
    Yaneva J; Leuba SH; van Holde K; Zlatanova J
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13448-51. PubMed ID: 9391045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.